Related Experiment Videos
Immunotherapy of allergic diseases
1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
International Archives of Allergy and Immunology
|January 1, 1993
Summary
Immunotherapy (IT) for IgE-mediated diseases has limitations due to crude extracts and risks. Research is advancing to improve safety and efficacy through new approaches like recombinant allergens and gene therapy.
Area of Science:
- Allergy and Immunology
- Immunotherapy Research
Background:
- Immunotherapy (IT) for IgE-mediated allergic diseases has been utilized since 1911.
- Current methods face challenges with crude allergen extracts, undefined epitopes, and potential severe adverse reactions, including anaphylaxis.
Purpose of the Study:
- To review the historical context and current limitations of traditional immunotherapy.
- To explore emerging research and future directions for improving the risk-benefit ratio of allergy treatments.
Main Methods:
- Review of existing literature on immunotherapy for IgE-mediated diseases.
- Discussion of advancements in pharmacotherapy and novel IT strategies.
- Exploration of future therapeutic avenues such as recombinant allergens and gene targeting.
Main Results:
- Traditional immunotherapy, while established, has significant drawbacks.
- Ongoing research focuses on enhancing allergen specificity and reducing adverse events.
- New approaches aim to modulate immune responses more precisely.
Conclusions:
- Despite limitations and risks, immunotherapy remains a key treatment for allergic diseases.
- Future advancements in molecular biology and immunology promise safer and more effective immunotherapies.
- Targeted therapies offer significant potential for managing IgE-mediated conditions.